To document the internal industry practice of engineering maximal palatability through precise fat-sugar-salt ratios, examine the documented gap between industry knowledge and regulatory disclosure requirements, and quantify the downstream public health cost externalities this practice generates.

Systematic review of litigation-surfaced industry documents, peer-reviewed neurological research on palatability engineering mechanisms, regulatory gap analysis comparing food, tobacco, and pharmaceutical disclosure frameworks, and economic burden-of-disease modeling from epidemiological databases.

Processed food manufacturers employ dedicated sensory scientists to identify the "bliss point" — the precise combination of sugar, fat, and salt at which consumer craving is maximized and self-regulation is neurologically impaired.

This practice is documented in internal industry communications surfaced through litigation: Kraft, Nabisco, and General Mills internal R&D memos from the 1980s-2000s explicitly reference palatability optimization as a competitive differentiator distinct from nutritional value.

Howard Moskowitz, the food scientist credited with formalizing bliss point methodology, applied the framework commercially for Dr Pepper, Campbell Soup, and Vlasic, and his methodology became standard across the industry by the 1990s.

Neuroimaging research published in Nature Neuroscience (2010, Johnson & Kenny) demonstrated that ultra-palatable food engineered to hit these ratios produces dopamine receptor downregulation in rats indistinguishable from cocaine exposure patterns, providing a mechanistic basis for behavioral addiction.

Despite this documented industry knowledge, no existing regulatory framework in the US, EU, or UK requires disclosure of sensory optimization research in product development files, nor does any framework impose a duty of care analogous to tobacco disclosure requirements.

The economic externality is substantial: a 2023 BMJ analysis estimated that ultra-processed food consumption accounts for approximately $50 billion annually in direct US healthcare costs attributable to diet-related metabolic disease, the majority concentrated in products formulated to hit bliss point thresholds.

Current food labeling regulations address ingredient quantities but not engineering intent, creating a structural asymmetry where manufacturers possess documented evidence of overconsumption design while regulators lack authority to compel its disclosure.